- ASCO® 2024
- Yale Cancer Answers
- ASH CME Series
- Smilow Shares with Primary Care
- Grand Rounds
- Head and Neck
- Gynecologic
- Benign Hematology
- Breast
- GI
- Lung
- GU
- Hematologic Oncology
- Brain
- Cancer Screening
- DEI (Diversity, Equity and Inclusion)
- 2021 ASH Highlights
- General Events
- Events
Playback speed
10 seconds
ASCO® 2024 Insights: "Impact of Exposure on Outcomes With Enfortumab Vedotin in Patients With Locally Advanced or Metastatic Urothelial Cancer"
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Daniel Petrylak
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Daniel Petrylak
163 views
June 6, 2024
Chapters
Introduction & Enfortumab Vedotin Overview
00:00
Study Schema & Dose Modifications
01:26
Efficacy Across Different Doses & Trials
04:14
Dose Reduction Impact on Treatment Outcomes
07:30
Safety, Efficacy & Conclusion
09:45
Comments 0
Login to view comments.
Click here to Login
ASCO® 2024